A Randomized Controlled Trial of IV Ketorolac to Prevent Post-ERCP Pancreatitis
Status:
Not yet recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
Determine if IV ketorolac is an effective agent in the prevention of post-ERCP pancreatitis.
Determine if IV ketorolac provides improved post-procedure analgesia.
Determine if systemic mediators of inflammation are reduced in patients receiving IV
ketorolac following ERCP.